xbrl.rienks.biz
English 
Nederlands
Français
Deutsch Crucell N.V.
| Address | Exchange | Stocks (-: 06:00:00) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
0.00%Industry: Health Care
Sector: Biotechnology
Companies engaged in research into and development of biological substances for the purposes of drug discovery and diagnostic development, and which derive the majority of their revenue from either the sale or licensing of these drugs and diagnostic tools.
| Crucell N.V. | (CRXL) | Biotechnology |
| Fornix BioSciences N.V. | (FORBI) | Biotechnology |
| Galapagos | (GLPGA) | Biotechnology |
| Pharming Group N.V. | (PHARM) | Biotechnology |
| English | Dutch | |
| Annual Report 2009 (5.34 MB) (Deloitte) Annual Report 2008 (3.04 MB) (Deloitte) Annual Report 2007 (4.29 MB) (Deloitte) Form20-F 2006 (3.33 MB) (Ernst & Young) Annual Report 2005 (4.24 MB) (Ernst & Young) Annual Report 2004 (0.82 MB) (Ernst & Young) Annual Report 2003 (4.57 MB) (Ernst & Young) | Jaarverslag 2005 (1.07 MB) (Ernst & Young) Jaarverslag 2004 (1.53 MB) (Ernst & Young) Jaarverslag 2003 (0.89 MB) (Ernst & Young) |
News
| Gazette.Net: Constipation drug offers more potential for Bethesdas Sucampo (02 Feb)
After a successful phase 3 clinical trial, Sucampo Pharmaceuticals of Bethesda is ready to apply for U.S. regulatory approval to market its constipation drug to people who have bowel dysfunction from taking morphine and codeine for chronic, non-cancer pain... MannKind prices underwritten public offering of 31,250,000 units of common stock (03 Feb)MannKind Corporation today announced the pricing of an underwritten public offering of 31,250,000 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.6 of a share of its common stock... Chinese Pharmaceutical Market 2012-2022 (30 Jan)NEW YORK, Jan. 30, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Chinese Pharmaceutical Market 2012-2022 http://www.reportlinker.com/p0151197/Chinese-Pharmaceutical-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_MedicationReport ..... | Soligenix reports results from long-term stability studies of SGX204 anthrax vaccine (18 Jan)
Soligenix, Inc., a development stage biopharmaceutical company, announced today results from long-term stability studies of its proprietary DNI anthrax rPA subunit protein vaccine, known as SGX204... |
Financial Calendar
| Yearly result | Quaterly Results | Analyst & Investor Conference |
|---|---|---|
| 13-02-2007 | Q1 - | - |
| Q2 - | - | |
| AGM | Q3 - | - |
| - | Q4 - | - |
Annual Accounts Crucell N.V.